Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Prelude Therapeutics ( (PRLD) ) has issued an announcement.
Prelude Therapeutics reported its second-quarter 2025 financial results and provided updates on its clinical development pipeline. The company completed a Phase 1 study of its intravenous SMARCA2 degrader, PRT3789, and decided to pause its development to focus on the oral SMARCA2 degrader, PRT7732, which is currently in the seventh dosing cohort. Prelude also continues to advance its KAT6A degrader program and aims to file an IND in the first half of 2026. Financially, the company reported a net loss of $31.2 million for the quarter, with cash reserves expected to fund operations into the second quarter of 2026.
The most recent analyst rating on (PRLD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Prelude Therapeutics stock, see the PRLD Stock Forecast page.
Spark’s Take on PRLD Stock
According to Spark, TipRanks’ AI Analyst, PRLD is a Underperform.
Prelude Therapeutics faces significant financial hurdles due to ongoing losses and lack of revenue, which heavily impact its overall score. Technical analysis shows mixed short-term momentum, but long-term weakness persists. The valuation is challenged by a negative P/E ratio and lack of dividends. However, recent corporate developments, including promising clinical results and a solid cash runway, offer some positive aspects, albeit insufficient to offset the broader financial concerns.
To see Spark’s full report on PRLD stock, click here.
More about Prelude Therapeutics
Prelude Therapeutics is a clinical-stage precision oncology company focused on developing innovative medicines for cancer patients. The company specializes in creating first-in-class, highly selective SMARCA2 and KAT6A degraders, and is actively engaged in research on other precision oncology targets, including degrader antibody conjugates.
Average Trading Volume: 161,476
Technical Sentiment Signal: Sell
Current Market Cap: $47.31M
See more data about PRLD stock on TipRanks’ Stock Analysis page.